Breast cancer detection rate increased by up to 43 %!
Siemens Healthineers Haberleri | 11-04-2014
True 3D Breast Tomosynthesis¹ from Siemens shows one of the highest increases in breast cancer detection rates seen to date. Preliminary results from an ongoing screening study in Malmö² demonstrated an increased detection rate of 43 % ³, one of the highest seen in several ongoing screening studies. Also encouraging is the recall rate of 3.8 %, which is well below the level recommended by European guidelines4.
This study differs from others studies in Europe in that the increased detection rate was achieved from the reading of a single tomosynthesis (3D) acquisition rather than reading the results of 2D and 3D combined. This shows potential for screening with a single 3D volume, rather than using a combination of 2D and 3D. This would result in significant reductions in examination time, reading time and radiation dose as well as an increase in overall patient comfort.
True 3D Breast Tomosynthesis uses a unique 50° acquisition angle and the full resolution of the digital detector, combined with HD (high definition) volume reconstruction to provide volumes with high spatial and depth resolution. This is particularly important for avoiding artefacts and for the detection of smaller structures, such as microcalcification clusters5.
The study demonstrates that True 3D Breast Tomosynthesis can increase breast cancer detection rates and is a promising supplement to and even a potential replacement for 2D digital mammography in the future.
Uluslararası (İngilizce): +49 69 797 6602 Bizi Pazartesi - Cuma günleri 8.00 - 17.00 saatleri arasında arayabilirsiniz.
¹ 3D Breast tomosynthesis is not yet commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further information.
² Performance of one-view breast tomosynthesis versus two-view mammography in breast cancer screening: first results from the Malmö breast tomosynthesis screening trial Sophia Zackrisson, Department of Diagnostic Radiology, Lund University, Malmö, Sweden.
³ 1 view DBT MLO vs. 2 views DM CC, MLO. The statements by Siemens’ customers described herein are based on results that were achieved in the customer's unique setting. Since there is no "typical" hospital and many variables exist (e.g., hospital size, case mix, level of IT adoption) there can be no guarantee that other customers will achieve the same results.